With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already dynamic autoimmune therapy market will only increase. The first biosimilars to launch in this therapy area (infliximab  and Benepali ) have now been available for several years in Europe, and their uptake has been robust. With more adalimumab biosimilars forecast to launch in Europe over the next year, it will be critical for stakeholders active in the immune space to understand the dynamics of how adalimumab biosimilars will affect uptake of the reference brand, Humira (AbbVie), and other originator biologics. Along with physician awareness of, familiarity with, and perceptions of biosimilars in general and the launched adalimumab biosimilars in particular, we explore the drivers of and barriers to the uptake of adalimumab biosimilars in Germany. We discuss promotional efforts, as well as prescriber and nonprescriber profiles, and benchmark the agents against other available biosimilars to better understand the dynamics of the German biosimilar market.
- Are German physicians aware of Amgevita, Imraldi, Hulio, and Hyrimoz?
- What is driving and will drive the uptake of adalimumab biosimilars in Germany? What is the current level of use of Amgevita, Imraldi, Hulio, and Hyrimoz, and how will this use change over time?
- Have German physicians experienced pressure to prescribe Amgevita, Imraldi, Hulio, and/or Hyrimoz to patients?
- What promotional messages are sales representatives using with the reference brand, Humira, and the adalimumab biosimilars Amgevita, Imraldi, Hulio, and Hyrimoz?
Emerging Biosimilars is a three-wave series based on primary research data collected at one, six, and twelve months postcommercial launch. The research captures physicians’ awareness, perceptions, and use of biosimilars, as well as their impact on current therapies and anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Wave 1: February 2019
Wave 2: June 2019
Wave 3: January 2020
Survey of 30 rheumatologists, 30 gastroenterologists, and 30 dermatologists
Key metrics included
- Unaided and aided awareness of Amgevita, Imraldi, Hulio, and Hyrimoz
- Familiarity with and impressions of Amgevita, Imraldi, Hulio, and Hyrimoz
- Prescriber and nonprescriber profiles
- Willingness to prescribe Amgevita, Imraldi, Hulio, and Hyrimoz
- Performance of Amgevita, Imraldi, Hulio, and Hyrimoz on key attributes
- Sales representative frequency, reach, and satisfaction
- Benchmarking against previously launched biosimilars
- Immunology: Adalimumab Biosimilars Launch Tracking (Germany) Wave 2
- Emerging Biosimilars: Adalimumab Launch Tracker (W2)
Author(s): Hamzah Aideed, MSc
Hamzah Aideed is a Principal Analyst in the biosimilars team at Decision Resources Group. Hamzah’s responsibilities include conducting primary and secondary market research, generating key insights into biosimilars and the biopharmaceutical industry, and providing client support. His work in biosimilars encompasses four key therapy areas – immunology, oncology, endocrinology, and nephrology. Prior to joining DRG, Hamzah was a Senior Research Executive at Consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies, for bespoke ad-hoc consulting projects. He holds an in Biotechnology & Business Management from the University of Warwick and a in Biological Chemistry from Aston University.